BRAF V600E mutation is rare (3.7%) in Dysembryoplastic neuroepithelial tumors (DNT).
BRAF copy number gain is frequent (33%) in DNTs, being reported for the first time.
mTOR (89.7%) and MAPK (50%) activation in DNTs is shown on immunohistochemistry.
Activation of mTOR and MAPK pathways is independent of BRAF alterations.
Suggests a pathogenetic role; provides therapeutic targets in DNT patients.